First-line palliative systemic therapy alternated with oxaliplatin-based pressurized intraperitoneal aerosol chemotherapy for unresectable colorectal peritoneal metastases: A single-arm phase II trial (CRC-PIPAC-II)
European Journal of Surgical Oncology · 2024-09 · 50 (9) · 108487
DOI: 10.1016/j.ejso.2024.108487 ↗Kurz gefasst
Klinische Studie (Phase II) in der Zeitschrift European Journal of Surgical Oncology, 2024-09. Verfasst von Paulien Rauwerdink und 23 weiteren Autor:innen. Beteiligte Einrichtung: Department of Surgery, St. Antonius Hospital, Nieuwegein, Netherlands. Electronic address: p.rauwerdink@antoniusziekenhuis.nl. Hauptthemen laut MEDLINE: Peritoneal Neoplasms, Colorectal Neoplasms, Oxaliplatin, Palliative Care. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 78 Literaturangaben. Gefördert von: St Antonius Hospital.
Themen: Onkologische Pflege
Abstract (Originalsprache)
BACKGROUND: Palliative systemic therapy alternated with electrostatic precipitation oxaliplatin-based pressurized intraperitoneal aerosol chemotherapy (ePIPAC) has never been prospectively investigated in patients with unresectable colorectal peritoneal metastases (CPM). The CRC-PIPAC-II study aimed to assess safety, feasibility and efficacy of such bidirectional therapy. METHODS: This two-center, single-arm, phase II trial enrolled chemotherapy-naïve patients to undergo three treatment cycles, consisting of systemic therapy (CAPOX, FOLFOX, FOLFIRI, or FOLFOXIRI, all with bevacizumab) and oxaliplatin-based ePIPAC (92 mg/m2) with intravenous leucovorin (20 mg/m2) and 5-fluorouracil (400 mg/m2). Primary outcome were major treatment-related adverse events. Secondary outcomes included minor events, tumor response, progression-free survival (PFS) and overall survival (OS). RESULTS: Twenty patients completed 52 treatment cycles. Fifteen major events occurred in 7 patients (35 %): 5 events (33 %) related to systemic therapy; 5 (33 %) related to ePIPAC; and 5 (33 %) were biochemical events. No treatment-related deaths occurred. All patients experienced minor events, mostly abdominal pain, nausea and peripheral sensory neuropathy. After treatment, radiological, pathological, cytological, and biochemical response was observed in 0 %, 88 %, 38 %, and 31 % of patients respectively. Curative surgery was achieved in one patient. Median PFS was 10.0 months (95 % confidence interval [CI] 8.0-13.0) and median OS was 17.5 months (95 % CI 13.0-not reached). CONCLUSIONS: Combining palliative systemic therapy with oxaliplatin-based ePIPAC in patients with unresectable CPM was feasible and showed an acceptable safety profile. Treatment-induced response and survival are promising, yet further research is required to determine the additional value of ePIPAC to systemic therapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Surgery, St. Antonius Hospital, Nieuwegein, Netherlands. Electronic address: p.rauwerdink@antoniusziekenhuis.nl.
- Department of Surgery, Catharina Hospital, Eindhoven, Netherlands.
- Department of Surgery, St. Antonius Hospital, Nieuwegein, Netherlands.
- Department of Medical Oncology, St. Antonius Hospital, Nieuwegein, Netherlands.
- Department of Medical Oncology, Catharina Hospital, Eindhoven, Netherlands.
- Department of Pathology DNA, St. Antonius Hospital, Nieuwegein, Netherlands.
Förderung
- St Antonius Hospital
Zitieren
APA
Rauwerdink, P., van de Vlasakker, V. C. J., Wassenaar, E. C. E., Rovers, K. P., Los, M., Herbschleb, K. H., Creemers, G. M., Thijs, A. M. J., Raicu, M. G., Huysentruyt, C. J. R., van der Hoeven, E. J. R. J., Nederend, J., Peeters, R. Y. M., Deenen, M. J., Elias, S. G., Fijneman, R. J. A., Constantinides, A., Kranenburg, O., Burger, P. W. A., …, & Boerma, D. (2024). First-line palliative systemic therapy alternated with oxaliplatin-based pressurized intraperitoneal aerosol chemotherapy for unresectable colorectal peritoneal metastases: A single-arm phase II trial (CRC-PIPAC-II). European Journal of Surgical Oncology, 50(9), 108487. https://doi.org/10.1016/j.ejso.2024.108487
Vancouver
Rauwerdink P, van de Vlasakker VCJ, Wassenaar ECE, Rovers KP, Los M, Herbschleb KH, et al. First-line palliative systemic therapy alternated with oxaliplatin-based pressurized intraperitoneal aerosol chemotherapy for unresectable colorectal peritoneal metastases: A single-arm phase II trial (CRC-PIPAC-II). European Journal of Surgical Oncology. 2024;50(9):108487. doi:10.1016/j.ejso.2024.108487
BibTeX
@article{Rauwerdink2024,
author = {Rauwerdink, Paulien and van de Vlasakker, Vincent C J and Wassenaar, Emma C E and Rovers, Koen P and Los, Maartje and Herbschleb, Karin H and Creemers, Geert-Jan M and Thijs, Annemarie M J and Raicu, Mihaela G and Huysentruyt, Clément J R and van der Hoeven, Erik J R J and Nederend, Joost and Peeters, Rifka Y M and Deenen, Maarten J and Elias, Sjoerd G and Fijneman, Remond J A and Constantinides, Alexander and Kranenburg, Onno and Burger, Pim W A and Nienhuijs, Simon W and Wiezer, René J and Lurvink, Robin J and de Hingh, Ignace H J T and Boerma, Djamila},
title = {First-line palliative systemic therapy alternated with oxaliplatin-based pressurized intraperitoneal aerosol chemotherapy for unresectable colorectal peritoneal metastases: A single-arm phase II trial (CRC-PIPAC-II)},
journal = {European Journal of Surgical Oncology},
year = {2024},
volume = {50},
number = {9},
pages = {108487},
doi = {10.1016/j.ejso.2024.108487}
}
EUVIMED